Defective γδ T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients

Experimental Hematology

Volumn 37, Issue 7, 2009, Pages 838-848

  Gaafar, Ameera ^a   Aljurf, Mahmoud Deeb ^b   Al Sulaiman, Abdullah ^a   Iqniebi, Alia ^a   Manogaran, Pulicat S ^c   Mohamed, Gamal Eldin H ^d   Al Sayed, Adher ^b   Alzahrani, Hazaa ^b   Alsharif, Fahad ^b   Mohareb, Fahad ^b   Ajarim, Dahish ^b   Tabakhi, Abdelghani ^e   Al Hussein, Khalid ^a  

^a Histocompatibility and Immunogenetics   (Saudi Arabia)

^b King Faisal Heart Institute   (Saudi Arabia)

^c Flow Cytometry   (Saudi Arabia)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e Laboratory Medicine   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; INTERLEUKIN 6; PAMIDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GRANZYME; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL STRAIN MCF 7; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DATA ANALYSIS; DAUDI CELL; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME POLYMORPHISM; EX VIVO STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BREAST TUMOR; CASE CONTROL STUDY; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COHORT STUDIES; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMIDAZOLES; IMMUNOPHENOTYPING; INTERLEUKIN-6; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67049107842     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.04.003     Document Type: Article

References (42)

1. Aljurf M., Ezzat A., and Omusa M. Emerging role of γδ T-cells in health and disease. Blood Rev 16 (2002) 203-206
2. Doherty P.C. The function of γδ T cells. Br J Haematol 81 (1992) 321-324
3. Modlin R.L., Pirmez C., Hofman F.M., et al. Lymphocytes bearing antigen-specific γδ T-cell receptors accumulate in human infectious disease lesions. Nature 339 (1989) 544-548
4. Smyth M.J., Godfrey D.I., and Trapani J.A. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2 (2001) 293-299
5. Girardi M. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol 126 (2006) 25-31
6. Ensslin A.S., and Formby B. Comparison of cytolytic and proliferative activities of human γδ and αβ T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst 83 (1991) 1564-1569
7. Kunzmann V., and Wilhelm M. Anti-lymphoma effect of γδ T cells. Leuk Lymphoma 46 (2005) 671-680
8. Dolstra H., Preijers F., Van de Wiel-van Kemenade E., Schattenberg A., Galama J., and de Witte T. Expansion of CD8 + CD57 + T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 90 (1995) 300-307
9. Duval M., Yotnda P., Bensussan A., et al. Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia. Leukemia 9 (1995) 863-868
10. Kunzmann V., Bauer E., Feurle J., Weissinger F., Tony H.P., and Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. [see comment]. Blood 96 (2000) 384-392
11. Sicard H., Al Saati T., Delsol G., and Fournie J.J. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 7 (2001) 711-722
12. Girardi M., Oppenheim D.E., Steele C.R., et al. Regulation of cutaneous malignancy by γδ T cells. [see comment]. Science 294 (2001) 605-609
13. Smyth M.J., Thia K.Y., Street S.E., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191 (2000) 661-668
14. Kato Y., Tanaka Y., Tanaka H., Yamashita S., and Minato N. Requirement of species-specific interactions for the activation of human γδ T cells by pamidronate. J Immunol 170 (2003) 3608-3613
15. Kabelitz D., Wesch D., Pitters E., and Zoller M. Potential of human γδ T lymphocytes for immunotherapy of cancer. Int J Cancer 112 (2004) 727-732
16. Dieli F., Gebbia N., Poccia F., et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102 (2003) 2310-2311
17. Dieli F., Poccia F., Lipp M., et al. Differentiation of effector/memory Vδ2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 198 (2003) 391-397
18. Wilhelm M., Kunzmann V., Eckstein S., et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102 (2003) 200-206
19. Mariani S., Muraro M., Pantaleoni F., et al. Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19 (2005) 664-670
20. Gutierrez L.S., Eliza M., Niven-Fairchild T., Naftolin F., and Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat (1999) 245-253
21. Brenner B.G., McCrea E.L., and Margolese R.G. Cytolysis of mammary tumor targets by resting, interleukin-2 stimulated and in vitro cultured peripheral blood lymphocytes from breast cancer patients. Anticancer Res 8 (1988) 653-658
22. Gao Y., Yang W., Pan M., et al. γδ T cells provide an early source of interferon gamma in tumor immunity. J Exp Med 198 (2003) 433-442
23. Johnstone R.W., Cretney E., and Smyth M.J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93 (1999) 1075-1085
24. Shtil A.A., Turner J.G., Dalton W.S., and Yu H. Alternative pathways of cell death to circumvent pleiotropic resistance in myeloma cells: role of cytotoxic T-lymphocytes. Leuk Lymphoma 38 (2000) 59-70
25. McIlroy D., Cartron P.F., Tuffery P., et al. A triple-mutated allele of granzyme B incapable of inducing apoptosis. Proc Natl Acad Sci U S A 100 (2003) 2562-2567
26. Gaafar A., Veress B., Permin H., Kharazmi A., Theander T.G., and el Hassan A.M. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol 91 (1999) 314-320
27. Han D., Xu X., Baidal D., et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 53 (2004) 2281-2290
28. Campbell M.J., and Gardner M.J. Calculating confidence intervals for some non-parametric analyses. Br Med J (Clin Res Ed.) 296 (1988) 1454-1456
29. Diehl S., Anguita J., Hoffmeyer A., et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13 (2000) 805-815
30. Kunzmann V., Bauer E., and Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340 (1999) 737-738
31. Alam S.M., Clark J.S., Leech V., Whitford P., George W.D., and Campbell A.M. T cell receptor gamma/delta expression on lymphocytes populations of breast cancer patients. Immunol Lett 31 (1992) 279-283
32. Fujimiya Y., Suzuki Y., Katakura R., et al. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) γδ T cells from glioblastoma patients. Clin Cancer Res 3 (1997) 633-643
33. Alexander A.A., Maniar A., Cummings J.S., et al. Isopentenyl pyrophosphate-activated CD56 + γδ T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res 14 (2008) 4232-4240
34. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196 (2002) 119-127
35. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. [see comment]. Nat Immunol 3 (2002) 991-998
36. Sato K., Kimura S., Segawa H., et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116 (2005) 94-99
37. Darmon A.J., Nicholson D.W., and Bleackley R.C. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377 (1995) 446-448
38. Mullbacher A., Waring P., Tha Hla R., et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci U S A 96 (1999) 13950-13955
39. Pascoe M.D., Marshall S.E., Welsh K.I., Fulton L.M., and Hughes D.A. Increased accuracy of renal allograft rejection diagnosis using combined perforin, granzyme B, and Fas ligand fine-needle aspiration immunocytology. Transplantation 69 (2000) 2547-2553
40. Li B., Hartono C., Ding R., et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. [see comment]. N Engl J Med 344 (2001) 947-954
41. Shtil A.A., Turner J.G., Durfee J., Dalton W.S., and Yu H. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93 (1999) 1831-1837
42. Zaitsu M., Yamamoto K., Ishii E., et al. High frequency of QPY allele and linkage disequilibrium of granzyme-B in Epstein-Barr-virus-associated hemophagocytic lymphohistiocytosis. Tissue Antigens 64 (2004) 611-615